Health Care [ 8/12 ] | Biotechnology [ 49/73 ]
NASDAQ | Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States.
It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor.
The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 25 | -0.41 Increased by +10.87% | -0.43 Increased by +4.65% |
| May 8, 25 | -0.40 Increased by +9.09% | -0.44 Increased by +9.09% |
| Feb 28, 25 | -0.31 Increased by +56.94% | -0.49 Increased by +36.73% |
| Nov 13, 24 | -0.44 Increased by +20.00% | -0.49 Increased by +10.20% |
| Aug 8, 24 | -0.46 Increased by +2.13% | -0.49 Increased by +6.12% |
| May 10, 24 | -0.44 Increased by 0.00% | -0.47 Increased by +6.38% |
| Mar 1, 24 | -0.72 Decreased by -28.57% | -0.51 Decreased by -41.18% |
| Nov 3, 23 | -0.55 Increased by +24.66% | -0.46 Decreased by -19.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 1.11 M Decreased by -97.05% | -52.59 M Increased by +4.95% | Decreased by -4.72 K% Decreased by -3.12 K% |
| Mar 31, 25 | 1.45 M Increased by +146.02% | -51.89 M Decreased by -13.39% | Decreased by -3.57 K% Increased by +53.91% |
| Dec 31, 24 | 2.18 M Decreased by -91.50% | -42.28 M Increased by +35.60% | Decreased by -1.94 K% Decreased by -657.97% |
| Sep 30, 24 | 209.00 K Increased by +N/A% | -52.52 M Decreased by -3.57% | Decreased by -25.13 K% Decreased by N/A% |
| Jun 30, 24 | 37.77 M Increased by +N/A% | -55.33 M Decreased by -30.53% | Decreased by -146.47% Decreased by N/A% |
| Mar 31, 24 | 591.00 K Increased by +N/A% | -45.76 M Decreased by -16.15% | Decreased by -7.74 K% Decreased by N/A% |
| Dec 31, 23 | 25.69 M Increased by +393.13% | -65.64 M Decreased by -67.10% | Decreased by -255.50% Increased by +66.11% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -50.71 M Decreased by -41.99% | Decreased by N/A% Decreased by N/A% |